<?xml version="1.0" encoding="UTF-8"?>
<p id="par0095">The timelines should be accelerated to develop not only vaccines but also immune-based antibody therapies and antiviral drugs (
 <xref rid="bib0010" ref-type="bibr">Bossart et al., 2012</xref>, 
 <xref rid="bib0015" ref-type="bibr">Broder et al., 2013</xref>, 
 <xref rid="bib0065" ref-type="bibr">Geisbert et al., 2014</xref>, 
 <xref rid="bib0050" ref-type="bibr">Elshabrawy et al., 2014</xref>, 
 <xref rid="bib0150" ref-type="bibr">Satterfield et al., 2016</xref>, 
 <xref rid="bib0145" ref-type="bibr">Rottingen et al., 2017</xref>). Prior to the Ebola pan-epidemic in West Africa there were only unlicensed, early-stage candidate Ebola vaccines, immune-based antibodies, and potential antiviral drugs, as is the case today for these three types of Nipah virus countermeasure in humans.
</p>
